

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 13, 2017**

**AKERS BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**New Jersey**

(State or other jurisdiction  
of incorporation)

**333-190456**

(Commission  
File Number)

**22-2983783**

(IRS Employer  
Identification No.)

**201 Grove Road  
Thorofare, NJ 08086**

(Address of Principal Executive Offices)

**(856) 848-2116**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 8.01 Other Events.**

On January 13, 2017, Akers Biosciences, Inc., a New Jersey corporation (the “Company”), issued a press release announcing that Joseph Gunnar & Co., LLC, the underwriter in the Company’s public offering announced in a Current Report on Form 8-K filed with the Securities and Exchange Commission on January 10, 2017, has elected to exercise its over-allotment option, pursuant to its underwriting agreement with the Company, to purchase an additional 122,500 shares of the Company’s common stock at a price of \$1.20 per share, before deducting underwriting discounts and commissions, and additional warrants to purchase up to 61,250 shares of the Company’s common stock with an exercise price of \$1.50.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press Release issued by the Company entitled “Issue of Equity,” dated January 13, 2017.*

*\*filed herewith*

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AKERS BIOSCIENCES, INC.**

Date: January 13, 2017

By: /s/ John J. Gormally  
John J. Gormally  
Chief Executive Officer

---



*This announcement contains inside information*

**Akers Biosciences, Inc.**

**Issue of Equity**

Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the “Company”), a developer of rapid health information technologies, announces that, further to the public offering announced on January 10, 2017 (the “Offering”), Joseph Gunnar & Co., LLC, the sole book-running manager for the Offering, has elected to exercise its over-allotment option, pursuant to its underwriting agreement with the Company, to purchase an additional 122,500 common shares from the Company at \$1.20 per share with the issuance of a further 61,250 warrants with an exercise price of \$1.50 (the “Warrants”). As a result, the gross proceeds from the Offering, excluding any proceeds on the exercise of the Warrants, are now expected to increase to \$2,147,400, before deducting the underwriting discount and estimated offering expenses.

The Company has applied for the admission of the additional 122,500 common shares to AIM and this is expected to take place on January 13, 2017 (“Admission”). Following Admission, the Company’s issued share capital will consist of 7,242,045 common shares with no common shares held in treasury. Therefore, the above figure of 7,242,045 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure and Transparency Rules.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement and accompanying base prospectus relating to the Offering may be obtained from Joseph Gunnar & Co, LLC, Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, telephone: 212-440-9600, email: [prospectus@jgunnar.com](mailto:prospectus@jgunnar.com).

**About Akers Biosciences, Inc.**

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company’s state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at [www.akersbio.com](http://www.akersbio.com). Follow us on Twitter [@AkersBio](https://twitter.com/AkersBio).

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

---

## Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

### For more information:

Akers Biosciences, Inc.  
John J. Gormally, Chief Executive Officer  
Raymond F. Akers, Jr. PhD, Co-founder and Chief Scientific Director  
Tel. +1 856 848 8698

Taglich Brothers, Inc. (Investor Relations)  
Chris Schreiber  
Tel. +1 917 445 6207  
Email: [cs@taglichbrothers.com](mailto:cs@taglichbrothers.com)

finnCap (UK Nominated Adviser and Broker)  
Adrian Hargrave / Scott Mathieson (Corporate Finance)  
Steve Norcross (Broking)  
Tel. +44 (0)20 7220 0500

Vigo Communications (Global Public Relations)  
Ben Simons / Fiona Henson  
Tel. +44 (0)20 7830 9700  
Email: [akers@vigocomms.com](mailto:akers@vigocomms.com)

---

